Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Plasma cell 1Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Warts 6Melanoma 5Neoplasms 3Urinary Bladder Neoplasms 1Sarcoma 1Ovarian Neoplasms 1Neoplasms, Plasma Cell 1Neoplasm Metastasis 1Esophageal Neoplasms 1Chondrosarcoma 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Adenocarcinoma 1

Interventions

Doxorubicin 80Ifosfamide 54Radiotherapy 43Filgrastim 41Gemcitabine 38Cyclophosphamide 34Etoposide 26Vincristine 24Cisplatin 24Docetaxel 23pazopanib 21Trabectedin 19Carboplatin 17pembrolizumab 15Peripheral Blood Stem Cell Transplantation 14eribulin 12Mesna 12Melphalan 12Sorafenib 11Sirolimus 11Irinotecan 11Granulocyte Colony-Stimulating Factor 11Bevacizumab 11Topotecan 10Paclitaxel 10Imatinib Mesylate 10Chemotherapy, Adjuvant 10pegfilgrastim 9Temozolomide 9Surgical Procedures, Operative 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Sarcoma × resiquimod × Clear all
NCT00948961 2016-06-27

A Study of CDX-1401 in Patients With Malignancies Known to Express NY-ESO-1

Celldex Therapeutics

Phase 1/2 Completed
70 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicPlasma cellSarcomaThoracic

Adenocarcinoma, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Chondrosarcoma, Esophageal Neoplasms, Melanoma, Ovarian Neoplasms, Sarcoma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡